2026 Summer Intern PhD Student - Chemical Process Development at Bristol-Myers Squibb

New Brunswick, New Jersey, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Currently enrolled in an accredited university program seeking a PhD degree in Chemistry
Expected to graduate between Fall 2026 and end of 2027
GPA of 3.0 or greater (must include GPA on resume for consideration)
Good oral/written communication skills
Ability to work in a team environment
Authorized to work in the US both at the time of hire and for the duration of employment (no immigration or visa sponsorship available)

Responsibilities

Work with mentors for ~10 weeks on a guided research project within a CPD Project Team
Participate in orientation, including overview of company structure, products, and brands
Gain exposure to GPS and PD organizations, senior management, and business leaders
Deliver a formal presentation at the end of the internship
Engage in mentor program and formal review and feedback sessions

Skills

Organic Chemistry

Analytical Chemistry

Chemical Engineering

Process Development

Chemical Synthesis

Scale-up

Sustainable Processes

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free